TY - JOUR
T1 - Rare variants in PLXNA4 and Parkinson's disease
AU - Schulte, Eva C.
AU - Stahl, Immanuel
AU - Czamara, Darina
AU - Ellwanger, Daniel C.
AU - Eck, Sebastian
AU - Graf, Elisabeth
AU - Mollenhauer, Brit
AU - Zimprich, Alexander
AU - Lichtner, Peter
AU - Haubenberger, Dietrich
AU - Pirker, Walter
AU - Brücke, Thomas
AU - Bereznai, Benjamin
AU - Molnar, Maria J.
AU - Peters, Annette
AU - Gieger, Christian
AU - Müller-Myhsok, Bertram
AU - Trenkwalder, Claudia
AU - Winkelmann, Juliane
N1 - Funding Information:
The authors have read the journal’s policy and have the following conflicts of interest to declare: Dr. ECS, Mr. IM, Dr. DC, Mr. DCE, Mr. SE and Mrs. EG report no disclosures. Dr. BM received travel compensation from Novartis and Boehringer-Ingelheim, lecturing fees from Orion and Glaxo-Smith-Kline, grant support from GE Healthcare, Boehringer-Ingelheim, Desitin, TEVA-Pharma, and serves as a consultant to Bayer-Schering Pharma and the Michael J. Fox Foundation for Parkinson’s Disease Research. Dr. DH received speaker honoraria from Ipsen Pharma. Dr. WP received speaker honoraria from AOP Orphan Pharma, Medtronic Inc., Novartis, Boehringer-Ingelheim, Abbott Pharm and UCB as well as travel compensation from Ipsen Pharma, Boehringer-Ingelheim, and Medtronic Inc. Dr. BB declares no conflicts of interest. Dr. MJM serves/has served on scientific advisory boards for Genzyme Europe B.V., received speaker honoria from Roche and serves as the Editor-in-Chief of the Hungarian edition of Neurology. Dr. AZ, Dr. TB, Dr. PL, Dr. AP, Dr. CG and Dr. BMM report no disclosures. Dr. CT serves on scientific advisory boards for Boehringer Ingelheim and UCB, has received speaker honoraria from Boehringer Ingelheim, UCB, and Mundipharma as well as travel compensation from UCB, Boehringer-Ingelheim, and Mundipharma. Dr. JW serves on a scientific advisory board for UCB, has received speaker honoraria from UCB and Vifor Pharma. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
PY - 2013/11/11
Y1 - 2013/11/11
N2 - Approximately 20% of individuals with Parkinson's disease (PD) report a positive family history. Yet, a large portion of causal and disease-modifying variants is still unknown. We used exome sequencing in two affected individuals from a family with late-onset familial PD followed by frequency assessment in 975 PD cases and 1014 ethnically-matched controls and linkage analysis to identify potentially causal variants. Based on the predicted penetrance and the frequencies, a variant in PLXNA4 proved to be the best candidate and PLXNA4 was screened for additional variants in 862 PD cases and 940 controls, revealing an excess of rare non-synonymous coding variants in PLXNA4 in individuals with PD. Although we cannot conclude that the variant in PLXNA4 is indeed the causative variant, these findings are interesting in the light of a surfacing role of axonal guidance mechanisms in neurodegenerative disorders but, at the same time, highlight the difficulties encountered in the study of rare variants identified by next-generation sequencing in diseases with autosomal dominant or complex patterns of inheritance.
AB - Approximately 20% of individuals with Parkinson's disease (PD) report a positive family history. Yet, a large portion of causal and disease-modifying variants is still unknown. We used exome sequencing in two affected individuals from a family with late-onset familial PD followed by frequency assessment in 975 PD cases and 1014 ethnically-matched controls and linkage analysis to identify potentially causal variants. Based on the predicted penetrance and the frequencies, a variant in PLXNA4 proved to be the best candidate and PLXNA4 was screened for additional variants in 862 PD cases and 940 controls, revealing an excess of rare non-synonymous coding variants in PLXNA4 in individuals with PD. Although we cannot conclude that the variant in PLXNA4 is indeed the causative variant, these findings are interesting in the light of a surfacing role of axonal guidance mechanisms in neurodegenerative disorders but, at the same time, highlight the difficulties encountered in the study of rare variants identified by next-generation sequencing in diseases with autosomal dominant or complex patterns of inheritance.
UR - http://www.scopus.com/inward/record.url?scp=84893020365&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0079145
DO - 10.1371/journal.pone.0079145
M3 - Article
C2 - 24244438
AN - SCOPUS:84893020365
SN - 1932-6203
VL - 8
JO - PLoS ONE
JF - PLoS ONE
IS - 11
M1 - e79145
ER -